Omega Therapeutics CMO Yan Moore departs; appoints Kaan Certel as Chief Business Officer

Omega Therapeutics, Inc.

CMO Yan Moore's employment terminated effective May 31, 2024; separation agreement with severance per employment agreement.
Company expects seamless continuation of Phase 1/2 trial for OTX-2002 (hepatocellular carcinoma); search for successor underway.
Appointed Kaan Certel, Ph.D. as Chief Business Officer effective May 28, 2024; over 20 years of biopharma experience.
Dr. Certel to lead global business development and strategic partnerships.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Yan Moore

Chief Medical Officer

Omega Therapeutics, Inc.

Effective: 2024-05-31
Filed: May 30, 2024, 7:59 PM ET

On May 28, 2024, Omega Therapeutics, Inc. (the “Company”) and Yan Moore, M.D., the Company’s Chief Medical Officer, agreed to terminate his employment effective as of May 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yan Moore departed as Chief Medical Officer at Omega Therapeutics, Inc..

Action: agreed to terminate his employment
Role: Chief Medical Officer

Exact text from the filing

On May 28, 2024, Omega Therapeutics, Inc. (the “Company”) and Yan Moore, M.D., the Company’s Chief Medical Officer, agreed to terminate his employment effective as of May 31, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-066746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.